摘要
目的探讨达格列净联合比索洛尔在急性ST段抬高型心肌梗死(ST-segment elevation myocardial infarction,STEMI)接受经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)患者中的应用效果。方法选取92例STEMI患者作为研究对象,随机分为联合组(给予达格列净联合比索洛尔治疗,n=46)、单一组(给予比索洛尔治疗,n=46)。比较2组的疗效,心脏功能指标、定量血流分数(quantitative flow ratio,QFR)、心肌损伤及灌注指标、心血管风险指标及不良反应的发生情况。结果治疗后,联合组的总有效率为89.13%,显著高于单一组的71.74%(P<0.05)。2组的QFR、左心室射血分数(left ventricular ejection fraction,LVEF)、心肌梗死溶栓(thrombolysis in myocardial infarction,TIMI)血流3级占比、ST段回落值(ST segment recovery value,STR)均显著升高,且联合组均显著高于单一组(P<0.05);2组的左心室收缩末期内径(left ventricular end-systolic dimension,LVESD)、左心室舒张末期内径(left ventricular end-diastolic dimension,LVEDD)、肌红蛋白(Myoglobin)、肌酸激酶同工酶MB(creatine kinase-MB,CK-MB)、乳酸脱氢酶(lactate dehydrogenase,LDH)、心型脂肪酸结合蛋白(heart-type fatty acid binding protein,H-FABP)、血浆动脉粥样硬化指数(atherogenic index of plasma,AIP)、甘油三酯葡萄糖(triglyceride-glucose,TyG)指数、全血组织蛋白酶D(cathepsin D,CTSD)、缺血修饰白蛋白(ischemia modified albumin,IMA)水平均显著降低,且联合组均显著低于单一组(P<0.05)。2组不良反应发生率比较差异无统计学意义(P>0.05)。结论达格列净联合比索洛尔治疗STEMI经PCI患者具有显著疗效,能促进心功能恢复,改善冠状动脉血流灌注,减轻心肌损伤,并降低心血管风险指标,且安全性良好。
Objective To investigate the efficacy of dapagliflozin combined with bisoprolol in patients with acute ST-segment elevation myocardial infarction(STEMI)undergoing percutaneous coronary intervention(PCI).Methods Ninety-two STEMI patients admitted to Shaowu Municiple Hospital of Fujian Province were randomly divided into a combined group(treated with dapagliflozin combined with bisoprolol,n=46)and a single group(treated with bisoprolol,n=46).The therapeutic efficacy,cardiac function index,quantitative flow ratio(QFR),myocardial injury and perfusion index,cardiovascular risk indexes,and adverse reactions were compared between the 2 groups.Results After treatment,the total effective rate of the combined group was 89.13%,which was significantly higher than that of the single group of 71.74%(P<0.05).QFR,left ventricular ejection fraction(LVEF),the proportion of grade 3 flow in thrombolysis in myocardial infarction(TIMI)blood flow,and ST segment recovery value(STR)were significantly increased in both groups,and the combined group was significantly higher than that in single group(P<0.05).Left ventricular end-systolic diameter(LVESD),left ventricular end diastolic dimension(LVEDD),myoglobin,creatine kinase-MB(CK-MB),lactate dehydrogenase(LDH),cardiac fatty acid-binding protein(H-FABP),Plasma Atherosclerosis Index(AIP),triglyceride glucose(TyG)index,whole blood cathepsin D(CTSD),the levels of ischemia modified albumin(IMA)were all significantly decreased in both groups,and the combined group was significantly lower than the single group(P<0.05).There was no significant difference in the incidence of adverse reactions between the 2 groups(P>0.05).Conclusion Dapagliflozin combined with bisoprolol is effective in the treatment of STEMI patients after PCI,which can promote the recovery of cardiac function,improve coronary artery blood perfusion,alleviate myocardial injury,and reduce cardiovascular risk indicators,with good safety.
作者
何凌云
张敏
官梅光
陈伟
吴维玲
阮景明
HE Lingyun;ZHANG Min;GUAN Meiguang;CHEN Wei;WU Weiling;RUAN Jingming(Department of Cardiology,Shaowu Municipal Hospital,Shaowu 354000,China;Catheterization Room,Shaowu Municipal Hospital,Shaowu 354000,China;Department of Radiology,Shaowu Municipal Hospital,Shaowu 354000,China;Department of Pharmacy,Shaowu Municipal Hospital,Shaowu 354000,China;Department of Cardiology,Jinshan Branch,Provincial Hospital Affiliated to Fuzhou University,Fuzhou 350001,China)
出处
《西北药学杂志》
2025年第6期159-165,共7页
Northwest Pharmaceutical Journal
基金
南平市科技计划项目(编号:N2024LH035)。
